Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis - Top-Institutions - MDSpire

Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis

  • By

  • Jiangzhuo Wu

  • Hanbing Li

  • Ling Wei

  • Xiao Yan

  • Jiang Fang

  • Lin Peng

  • Xiaobo Zhao

  • July 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #4

    Hospital Clinic of Barcelona
    Hospital Clinic of Barcelona

    Barcelona, Catalonia

    Key Differentiators

    • Oncology

  • #5

    German Breast Group
    German Breast Group

    Neu-Isenburg, Hesse

    Key Differentiators

    • Oncology

Original Source(s)

Neoadjuvant chemotherapy with angiogenesis inhibitor in early-stage breast cancer: a systematic review and meta-analysis

  • by Jiangzhuo Wu, Hanbing Li, Ling Wei, Xiao Yan, Jiang Fang, Lin Peng, Xiaobo Zhao

  • July 15, 2026

Related Content

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis

Giant solid pseudopapillary neoplasm of the pancreas in an adolescent girl: a case report with narrative review

From associations to clinical practice: translating inflammatory-nutritional indices into a machine learning-driven model for breast cancer risk stratification with cross-ethnic validation